4 years ago

Owlstone Medical Secures $58 Million to Advance Breath Biopsy Technology

  • Owlstone Medical, a Cambridge UK-based global leader in Breath Biopsy® for applications in early disease detection and precision medicine, raised $58M in funding led by Horizons Ventures

  • The company intends to use the funds to accelerate the development and commercialization of these tests and facilitate further advancements in the Breath Biopsy platform

  • Owlstone Medical has developed a proprietary platform in Breath Biopsy capable of both use in routine diagnostic testing and in biomarker discovery.

      • ProblemHealthcare

      "early disease detection and precision medicine"

      Solution

      "developing Breath Biopsy platform for biomarker discovery and diagnostic testing"

      Covered on